Recent developments in the treatment of patients with HAE include kallikrein inhibitors such as lanadelumab and berotralstat, which have shown remarkable efficacy in reducing attack frequency and improving patient quality of life [18]. This evidence concerns the gene KLK4 and hereditary angioedema.